VK2735: A Tracking Guide for a GIP and GLP-1 Dual Agonist

VK2735 is a dual GIP and GLP-1 receptor agonist developed by Viking Therapeutics, in the same broad class as tirzepatide. It is being developed in both a once-weekly subcutaneous form and an oral tablet form. The subcutaneous version is in the Phase 3 VANQUISH program (VANQUISH-1 and VANQUISH-2), with VANQUISH-1 enrollment of roughly 4,650 adults completed in November 2025, while the Phase 2 VENTURE trials, including a 13-week oral dosing study, showed meaningful weight loss.

VK2735 is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.

What it does

• Activates GIP and GLP-1 receptors to suppress appetite and slow gastric emptying
• Drives fat loss in Phase 2 trials, in both oral and injectable forms
• Aims to let patients potentially move between injection and pill using one active agent

Typical protocol shape

In the trials, VK2735 is dose-escalated over weeks to a maintenance dose to limit GI effects. The subcutaneous form is once weekly; the oral tablet is dosed daily and is being evaluated in its own studies. Any dose figures are trial context only, never a recommendation.

What to track daily

• Appetite, portion sizes, and fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance for the subcutaneous form
• Grip strength or a simple lift to watch for muscle loss during rapid loss

Bloodwork worth doing

• Fasting glucose and HbA1c
• Lipid panel over time
• Note thyroid history given the incretin class signal

Realistic expectations

Phase 3 readouts will define real efficacy and safety; Phase 2 data are promising but preliminary. Weight loss is gradual and diet-dependent, and part of rapid loss can be lean mass, so protein and resistance training belong in the plan.

Common mistakes

• Treating a Phase 3 candidate as an available, characterized therapy
• Ignoring GI intolerance during escalation
• Neglecting muscle-preserving habits during loss

Safety notes

VK2735 is investigational and not FDA approved as of mid-2026. Expect incretin-class GI effects and heart-rate changes, and consider any non-trial access outside the evidence base. Use only with medical supervision.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.